R
Ryan White
Researcher at Amgen
Publications - 64
Citations - 1179
Ryan White is an academic researcher from Amgen. The author has contributed to research in topics: Signal transduction & Receptor. The author has an hindex of 20, co-authored 64 publications receiving 1072 citations.
Papers
More filters
Patent
Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
Patel Vinod F,Joseph L. Kim,Stephanie D. Geuns-Meyer,Stuart C. Chaffee,Victor J. Cee,Brian L. Hodous,Steven Bellon,Jean-Christophe Harmange,Philip R. Olivieri,Maya C. Thaman,Erin F. DiMauro,John L. Buchanan,David C. Mcgowan,Albrecht Brian,Holly L. Deak,Jean Bemis,Ryan White,Matthew W. Martin,Gregory J. Habgood,Paul Tempest,Craig E. Masse,William H. Buckner,Bradley J. Herberich,Russell Graceffa,Dawei Zhang,Shimin Xu,Kelvin Sham,Robert M. Rzasa,James R. Falsey,Partha P. Chakrabarti,Guo-Qiang Cao,Susan A. Tomlinson,Liping H. Pettus,Adrian L. Smith,Nick A. Paras,Liu Gang,Frenel Fils Demorin,Andrew Tasker,Anthony B. Reed +38 more
TL;DR: In this paper, a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions, are defined.
Patent
Aurora kinase modulators and method of use
Victor J. Cee,Holly L. Deak,Stephanie D. Geuns-Meyer,Bingfan Du,Brian L. Hodous,Matthew W. Martin,Hanh Nho Nguyen,Philip R. Olivieri,Kathleen Panter,Karina Romero,Laurie B. Schenkel,Ryan White +11 more
TL;DR: In this article, chemical compounds having a general formula (I), wherein A1-8, D, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases.
Journal ArticleDOI
Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Jean-Christophe Harmange,Matthew Weiss,Julie Germain,Anthony Polverino,George Borg,James Bready,Danlin Chen,Deborah Choquette,Angela Coxon,Tom DeMelfi,Lucian DiPietro,Nicholas Doerr,Juan Estrada,Julie Flynn,Russell Graceffa,Shawn Harriman,Stephen Kaufman,Daniel S. La,Alexander M. Long,Matthew W. Martin,Sesha Neervannan,Vinod F. Patel,Michele Potashman,Kelly Regal,Philip Roveto,Michael Schrag,Charlie Starnes,Andrew Tasker,Yohannes Teffera,Ling Wang,Ryan White,Douglas A. Whittington,Roger Zanon +32 more
TL;DR: A series of naphthyl-based compounds were synthesized as potential inhibitors of vascular endothelial growth factor (VEGF) receptors and demonstrated significant antitumor efficacy against established HT29 human colon adenocarcinoma xenografts implanted in athymic mice.
Journal ArticleDOI
Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity
Erin F. DiMauro,John Newcomb,Joseph J. Nunes,Jean Bemis,Christina Boucher,John L. Buchanan,William H. Buckner,Victor J. Cee,Lilly Chai,Holly L. Deak,Linda F. Epstein,Ted Faust,Paul Gallant,Stephanie D. Geuns-Meyer,Anu Gore,Yan Gu,Brad Henkle,Brian L. Hodous,Faye Hsieh,Xin Huang,Joseph L. Kim,Josie H. Lee,Matthew W. Martin,Craig E. Masse,David C. Mcgowan,Daniela Metz,Deanna Mohn,Kurt Morgenstern,Antonio J. Oliveira-dos-Santos,Vinod F. Patel,David Powers,Paul E. Rose,Stephen Schneider,Susan A. Tomlinson,Yanyan Tudor,Susan M. Turci,Andrew A. Welcher,Ryan White,Huilin Zhao,Li Zhu,Xiaotian Zhu +40 more
TL;DR: The synthesis and structure-activity relationships of a series of novel aminoquinazolines possessing in vitro mechanism-based potency and anti-inflammatory activity in the anti-CD3-induced production of interleukin-2 (IL-2) in mice are described.
Journal ArticleDOI
Novel 2-Aminopyrimidine Carbamates as Potent and Orally Active Inhibitors of Lck: Synthesis, SAR, and in Vivo Antiinflammatory Activity
Matthew W. Martin,John Newcomb,Joseph J. Nunes,David C. Mcgowan,Armistead David M,Christina Boucher,John L. Buchanan,William H. Buckner,Lilly Chai,Daniel Elbaum,Linda F. Epstein,Theodore Faust,Shaun Flynn,Paul Gallant,Anu Gore,Yan Gu,Faye Hsieh,Xin Huang,Josie H. Lee,Daniela Metz,Scot Middleton,Deanna Mohn,Kurt Morgenstern,Michael Morrison,Perry M. Novak,Antonio J. Oliveira-dos-Santos,David Powers,Paul E. Rose,Stephen Schneider,Stephanie Sell,Yanyan Tudor,Susan M. Turci,Andrew A. Welcher,Ryan White,Debra Zack,Huilin Zhao,Li Zhu,Xiaotian Zhu,Chiara Ghiron,Patricia Amouzegh,Monika Ermann,Jenkins James Edward,David N. Johnston,Spencer Napier,Eoin Christopher Power +44 more
TL;DR: The synthesis, structure-activity relationships, and pharmacological characterization of 2-aminopyrimidine carbamates, a new class of compounds with potent and selective inhibition of Lck, are described, and the most promising compound, 2,6-dimethylphenyl 2-2,4-bis(methyloxy)phenyl)carbamate exhibits good activity when evaluated in in vitro assays and in an in vivo model of T cell activation.